Hypophosphatasia - Pathophysiology and treatment;Hipofosfatasia - Fisiopatología y tratamiento

Actualizaciones en Osteologia

Volumn 8, Issue 3, 2012, Pages 164-182

  Millán, José Luis ^a   Plotkin, Horacio ^b  

^a BURNHAM INSTITUTE   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

Alkaline phosphatase; Asfotase alfa; Hypophosphatasia

Indexed keywords

ALKALINE PHOSPHATASE; ASFOTASE ALFA; OSTEOPONTIN;

BONE MINERALIZATION; ECHOGRAPHY; ELECTRON MICROSCOPY; ENZYME REPLACEMENT; HUMAN; HYPERCALCEMIA; HYPOPHOSPHATASIA; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; REVIEW; RICKETS; SCANNING ELECTRON MICROSCOPY; SEIZURE; TOOTH DEVELOPMENT;

EID: 84874593733     PISSN: 16698975     EISSN: 16698983     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Fraser D. Hypophosphatasia. Am J Med 1957; 22:730-46.
2. Greenberg CR, Taylor CL, Haworth JC, Seargeant LE, Philipps S, Triggs-Raine B, Chodirker BN. A homoallelic Gly317-->Asp mutation in ALPL causes the perinatal (lethal) form of hypophosphatasia in Canadian mennonites. Genomics 1993; 17:215-7.
3. Millan JL. Mammalian alkaline phosphatases. From biology to applications in medicine and biotechnology. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co; 2006.
4. Whyte M. Hypophosphatasia. In: Glorieux F, Jueppner H, Pettifor J, editors. Pediatric Bone. San Diego, CA: Elsevier (Academic Press); 2012. p. 771-94.
5. Fallon MD, Teitelbaum SL, Weinstein RS, Goldfischer S, Brown DM, Whyte MP. Hypophosphatasia: clinicopathologic comparison of the infantile, childhood, and adult forms. Medicine (Baltimore) 1984; 63:12-24.
6. Whyte MP, Teitelbaum SL, Murphy WA, Bergfeld MA, Avioli LV. Adult hypophosphatasia. Clinical, laboratory, and genetic investigation of a large kindred with review of the literature. Medicine (Baltimore) 1979; 58:329-47.
7. Whyte MP, Murphy WA, M. Fallon MD. Adult hypophosphatasia with chondrocalcinosis and arthropathy. Variable penetrance of hypophosphatasemia in a large Oklahoma kindred. Am J Med 1982; 72:631-41.
8. Wenkert D, Mcalister WH, Coburn SP, Zerega JA, Ryan LM, Ericson KL, Hersh JH, Mumm S, Whyte MP. Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res 2011; 26:2389-98.
9. Weiss MJ, Cole DE, Ray K, Whyte MP, Lafferty MA, Mulivor RA, Harris H. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci USA 1988; 85:7666-9.
10. Henthorn PS, Raducha M, Fedde KN, Lafferty MA, Whyte MP. Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia. Proc Natl Acad Sci USA 1992; 89:9924-8.
11. Henthorn PS, Whyte MP. Missense mutations of the tissue-nonspecific alkaline phosphatase gene in hypophosphatasia. Clin Chem 1992; 38:2501-5.
12. Ozono K, Yamagata M, Michigami T, et al. Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. J Clin Endocrinol Metab 1996; 81:4458-61.
13. Orimo H, Hayashi Z, Watanabe A, Hirayama T, Hirayama T, Shimada T. Novel missense and frameshift mutations in the tissue-nonspecific alkaline phosphatase gene in a Japanese patient with hypophosphatasia. Hum Mol Genet 1994; 3:1683-4.
14. Mornet E, Taillandier A, Peyramaure S, et al. Identification of fifteen novel mutations in the tissuenonspecific alkaline phosphatase (TNSALP) gene in European patients with severe hypophosphatasia. Eur J Hum Genet 1998; 6:308-14.
15. Mumm S, Jones J, Finnegan P, Whyte MP. Hypophosphatasia: molecular diagnosis of Rathbun's original case. J Bone Miner Res 2001; 16:1724-7.
16. Ali SY, Sajdera SW, Anderson HC. Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage. Proc Natl Acad Sci USA 1970; 67:1513-20.
17. Bernard GW. Ultrastructural localization of alkaline phosphatase in initial intramembranous osteogenesis. Clin Orthop Relat Res 1978; 218-25.
18. Morris DC, Masuhara K, Takaoka K, Ono K, Anderson HC. Immunolocalization of alkaline phosphatase in osteoblasts and matrix vesicles of human fetal bone. Bone Miner 1992; 19:287-98.
19. Anderson HC, Harmey D, Camacho NP, et al. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasiarelated mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol 2005; 166:1711-20.
20. Anderson HC, Hsu HH, Morris DC, Fedde KN, Whyte MP. Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. Am J Pathol 1997; 151:1555-61.
21. Anderson HC, Sipe JB, Hessle L, et al. Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol 2004; 164:841-7.
22. Meyer JL. Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 1984; 231:1-8.
23. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164:1199-209.
24. Hessle L, Johnson KA, Anderson HC, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 2002; 99: 9445-9.
25. Murshed M, Harmey D, Millan JL, Mckee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19:1093-104.
26. Johnson KA, Hessle L, Vaingankar S, et al. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 2000; 279:R1365-77.
27. Ciancaglini P, Yadav MC, Simao AM, et al. Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1-deficient matrix vesicles. J Bone Miner Res 2010; 25:716-23.
28. Majeska RJ, Wuthier RE. Studies on matrix vesicles isolated from chick epiphyseal cartilage. Association of pyrophosphatase and ATPase activities with alkaline phosphatase. Biochim Biophys Acta 1975; 391:51-60.
29. Moss DW, Eaton RH, Smith JK, Whitby LG. Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J 1967; 102:53-7.
30. Rezende AA, Pizauro JM, Ciancaglini P, Leone FA. Phosphodiesterase activity is a novel property of alkaline phosphatase from osseous plate. Biochem J 1994; 301 (Pt 2):517-22.
31. Robison R. The Possible Significance of Hexosephosphoric Esters in Ossification. Biochem J 1923; 17:286-93.
32. Yadav MC, Simao AM, Narisawa S, et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 2011; 26:286-97.
33. Coburn SP. Modeling vitamin B6 metabolism. Adv Food Nutr Res 1996; 40:107-32.
34. Jansonius JN. Structure, evolution and action of vitamin B6-dependent enzymes. Curr Opin Struct Biol 1998; 8:759-69.
35. Whyte MP, Landt M, Ryan LM, et al. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest 1995; 95:1440-5.
36. Chodirker BN, Coburn SP, Seargeant LE, Whyte MP, Greenberg CR. Increased plasma pyridoxal-5'-phosphate levels before and after pyridoxine loading in carriers of perinatal/ infantile hypophosphatasia. J Inherit Metab Dis 1990; 13:891-6.
37. Whyte MP, Mahuren JD, Fedde KN, Cole FS, Mccabe ER, Coburn SP. Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5'-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. J Clin Invest 1988; 81:1234-9.
38. Whyte MP, Mahuren JD, Vrabel LA, Coburn SP. Markedly increased circulating pyridoxal-5'phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest 1985; 76:752-6.
39. Narisawa S, Frohlander N, Millan JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn 1997; 208:432-46.
40. Narisawa S, Wennberg C, Millan JL. Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol 2001; 193:125-33.
41. Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, Macgregor GR. Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat Genet 1995; 11:45-51.
42. Fleshood HL, Pitot HC. O-phosphorylethanolamine ammonia lyase, a new pyridoxal phosphatedependent enzyme. Biochem Biophys Res Commun 1969; 36:110-8.
43. Fleshood HL, Pitot HC. The metabolism of Ophosphorylethanolamine in animal tissues. II. Metabolic regulation of O-phosphorylethanolamine phospho-lyase in vivo. Arch Biochem Biophys 1970; 141:423-9.
44. Millan JL, Whyte MP, Avioli LV, Fishman WH. Hypophosphatasia (adult form): quantitation of serum alkaline phosphatase isoenzyme activity in a large kindred. Clin Chem 1980; 26:840-5.
45. Harmey D, Johnson KA, Zelken J, et al. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res 2006; 21:1377-86.
46. Johnson K, Goding J, Van Etten D, et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003; 18: 994-1004.
47. Wennberg C, Hessle L, Lundberg P, et al. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res 2000; 15:1879-88.
48. Goldberg HA, Warner KJ, Li MC, Hunter GK. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect Tissue Res 2001; 42:25-37.
49. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 2005; 390:285-92.
50. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300 (Pt 3):723-8.
51. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000; 275:20197-203.
52. Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J 2004; 378:1083-7.
53. Addison WN, Masica DL, Gray JJ, Mckee MD. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 2010; 25:695-705.
54. Deeb AA, Bruce SN, Morris AA, Cheetham TD. Infantile hypophosphatasia: disappointing results of treatment. Acta Paediatr 2000; 89:730-3.
55. Sutton RA, Mumm S, Coburn SP, Ericson KL, Whyte MP. "Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res 2012; 27:987-94.
56. Cahill RA, Wenkert D, Perlman SA, et al. Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. J Clin Endocrinol Metab 2007; 92:2923-30.
57. Whyte MP, Kurtzberg J, Mcalister WH, et al. Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res 2003; 18:624-36.
58. Camacho PM, Painter S, Kadanoff R. Treatment of adult hypophosphatasia with teriparatide. Endocr Pract 2008; 14:204-8.
59. Doshi KB, Hamrahian AH, Licata AA. Teriparatide treatment in adult hypophosphatasia in a patient exposed to bisphosphonate: a case report. Clin Cases Miner Bone Metab 2009; 6:266-9.
60. Schalin-Jantti C, Mornet E, Lamminen A, Valimaki MJ. Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia. J Clin Endocrinol Metab 2010; 95: 5174-9.
61. Whyte MP, Mumm S, Deal C. Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 2007; 92:1203-8.
62. Gagnon C, Sims NA, Mumm S, et al. Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J Clin Endocrinol Metab 2010; 95:1007-12.
63. Laroche M. Failure of teriparatide in treatment of bone complications of adult hypophosphatasia. Calcif Tissue Int 2012; 90:250.
64. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32:426-38.
65. Chung TD, Sergienko E, Millan JL. Assay format as a critical success factor for identification of novel inhibitor chemotypes of tissue-nonspecific alkaline phosphatase from high-throughput screening. Molecules 2010; 15:3010-37.
66. Whyte MP, Valdes Jr. R, Ryan LM, McAlister WH. Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget's bone disease. J Pediatr 1982; 101:379-386.
67. Whyte MP, Mcalister WH, Patton LS, et al. Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients. J Pediatr 1984; 105:926-33.
68. Weninger M, Stinson RA, Plenk H, Jr., Bock P, Pollak A. Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. Acta Paediatr Scand 1989; 360(Suppl):154-60.
69. Millan JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 2008; 23:777-87.
70. Kasugai S, Fujisawa R, Waki Y, Miyamoto K, Ohya K. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res 2000; 15:936-43.
71. Nishioka T, Tomatsu S, Gutierrez MA, et al. Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab 2006; 88:244-55.
72. Yokogawa K, Miya K, Sekido T, et al. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001; 142:1228-33.
73. Fedde KN, Blair L, Silverstein J, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 1999; 14:2015-26.
74. Mckee MD, Nakano Y, Masica DL, et al. Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia. J Dent Res 2011; 90:470-6.
75. Foster BL, Nagatomo KJ, Tso HW, et al. Tooth root dentin mineralization defects in a mouse model of hypophosphatasia. J Bone Miner Res 2012; In press.
76. Yadav MC, Lemire I, Leonard P, et al. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone 2011; 49:250-6.
77. Yadav MC, De Oliveira RC, Foster BL, et al. Enzyme replacement prevents enamel defects in hypophosphatasia mice. J Bone Miner Res 2012; 27:1722-34.
78. Nociti FH, Jr., Berry JE, Foster BL, Get al. Cementum: a phosphate-sensitive tissue. J Dent Res 2002; 81:817-21.
79. Yamamoto S, Orimo H, Matsumoto T, et al. Prolonged survival and phenotypic correction of Akp2(-/-) hypophosphatasia mice by lentiviral gene therapy. J Bone Miner Res 2011; 26:135-42.
80. Matsumoto T, Miyake K, Yamamoto S, et al. Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase. Hum Gene Ther 2011; 22:1355-64.
81. Sugano H, Matsumoto T, Miyake K, et al. Successful gene therapy in utero for lethal murine hypophosphatasia. Hum Gene Ther 2012; 23:399-406.
82. Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012; 366:904-13.